PFS
CLDX icon

Prospera Financial Services’s Celldex Therapeutics CLDX Stock Holding History

Prospera Financial Services’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-7,754
Closed -$287K – 1127
2024
Q2 		$287K Buy
7,754
+1,932
+33% +$72.9K 0.01% 936
2024
Q1 		$244K Buy
+5,822
New +$239K 0.01% 976
2022
Q2 		– Sell
-2,622
Closed -$89K – 1772
2022
Q1 		$89K Buy
+2,622
New +$83.8K ﹤0.01% 1150
2020
Q4 		– Sell
-3,738
Closed -$55K – 823
2020
Q3 		$55K Buy
+3,738
New +$43.8K 0.02% 584

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Prospera Financial Services's CLDX Position: Q3 2024 in Review

Prospera Financial Services sold out of Celldex Therapeutics (CLDX) in Q3 2024, closing a stake of 7,754 shares — an estimated $287K sold.

Prospera Financial Services first reported a position in CLDX in Q3 2020 and held it in 4 quarters. The position peaked at $287K in Q2 2024. 176 funds tracked by Wall St. Rank hold CLDX as of Q3 2024.

  • Prospera Financial Services reported no remaining Celldex Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Prospera Financial Services sold 7,754 Celldex Therapeutics shares in Q3 2024, an estimated $287K.
  • Prospera Financial Services first reported a position in Celldex Therapeutics in Q3 2020 and held it in 4 quarters.
  • Prospera Financial Services's Celldex Therapeutics position peaked at $287K in Q2 2024.
  • 176 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2024.

Based on Prospera Financial Services's 13F filing for Q3 2024, filed 7 Nov 2024.